Cite
Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study
MLA
Alessandra Anna Anna Prete, et al. “Immunotherapy in RAS Mutant MCRC: Could CTLA-4 Blockade Increase the Efficacy of Anti PD-1 Agents? Preliminary Clinical Results of the NERDY Study.” Journal of Clinical Oncology, vol. 41, Feb. 2023, p. 218. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........916567ed9ed120e3580fb1b2b08ff8f6&authtype=sso&custid=ns315887.
APA
Alessandra Anna Anna Prete, Rossana Intini, Vittoria Matilde Piva, Valentina Angerilli, Francesca Daniel, Giulia Barsotti, Maria Caterina De Grandis, Krisida Cerma, Giada Munari, Gianmarco Ricagno, Aldo Montagna, Chiara De Toni, Silvia Rossi, Riccardo Cerantola, Cosimo Rasola, Francesca Schiavi, Matteo Fassan, Francesca Bergamo, Vittorina Zagonel, & Sara Lonardi. (2023). Immunotherapy in RAS mutant mCRC: Could CTLA-4 blockade increase the efficacy of anti PD-1 agents? Preliminary clinical results of the NERDY study. Journal of Clinical Oncology, 41, 218.
Chicago
Alessandra Anna Anna Prete, Rossana Intini, Vittoria Matilde Piva, Valentina Angerilli, Francesca Daniel, Giulia Barsotti, Maria Caterina De Grandis, et al. 2023. “Immunotherapy in RAS Mutant MCRC: Could CTLA-4 Blockade Increase the Efficacy of Anti PD-1 Agents? Preliminary Clinical Results of the NERDY Study.” Journal of Clinical Oncology 41 (February): 218. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........916567ed9ed120e3580fb1b2b08ff8f6&authtype=sso&custid=ns315887.